ArtVentive Medical Group, Inc., an innovative, multi-faceted medical device company, commenced the launch of its flagship occlusion device product, the ArtVentive Endoluminal Occlusion System (EOS) at the Global Embolization Symposium and Technologies (GEST) in New York. The introduction in the United States follows the initial commercialization in the EU last year.
Dr. Jafar Golzarian, MD, GEST co-founder and director of Interventional Radiology and Vascular Imaging at the University of Minnesota presented the ArtVentive EOS device to a standing room only audience of over 200 vascular surgeons and interventional radiologists in a session titled the “New World of Micro Plugs.”
Dr. Marc Sapoval, GEST co-chairman and Professor of Clinical Radiology and chair of the Cardiovascular Radiology Department Georges Pompidou Hospital, Paris, France deployed the device during the demonstration at the “Master class and Materials: Coils and Plugs”.
Dr. Adriaan Moelker, MD, PhD, head Section Interventional Radiology at the Department of Radiology, Erasmus University Medical Center in Rotterdam, the largest interventional radiology practice in the Netherlands, described his experience as an early adapter of EOS. His pioneering usage of the vascular occlusion device was demonstrated in multiple case studies conducted at his hospital and he reported his clinical experience and resultant benefits of using the ArtVentive EOS device in multiple arterial and venous applications.
Dr. Moelker explained that he and his team “repeatedly used ArtVentive EOS at Erasmus University Medical Center in our practice of embolization procedures. The ArtVentive EOS device has a unique ability to act immediately, instantly occluding targeted vessels. EOS reduces procedure time substantially compared to conventional coil insertion, decreasing the amount of radiation received by both medical personnel and patient. EOS™ has great impact on our everyday practice, significantly reducing expenses and the negative effects of use of radiation during the procedure.”
Leon Rudakov, PhD, president and chief technology officer of ArtVentive, commented, “This year, ArtVentive has established two Centers in the United States at George Washington University and TUFTS with interventional radiologists that are committed to assisting us in introducing our product to other professionals and hospitals. EOS is CE-marked and recently received FDA 510(k) approval in Q4 2015 and we are now strategically expanding our European and US operations through selecting distributors and proctoring centers.”
“GEST 2016 provided an ideal platform for us to launch our US commercialization efforts with our exposure to the top professionals in the world and the opportunity to proctor over 50 physicians with hands-on training on the use of EOS. ArtVentive demonstrated how EOS provides immediate and permanent occlusion, with key competitive advantages and clinical benefits over traditional methods and devices. We are off to a great start in 2016 and look forward to continuing our product launch in the US and expanding our EOS technology platform beyond peripheral vascular to other critical treatments in the rapidly growing field of interventional radiology, vascular surgery and beyond.”